Navigation Links
Latest Addition to Patent Portfolio Hammers Prescription Drug Abuse and Creates New Market
Date:5/17/2011

ormulation techniques to solve complex problems. Pisgah has identified salt forms of nearly all the commercial opiates used in prescription pain medications which will impart abuse deterrent features. The drug abuser will find it more difficult to separate the active ingredient from the dosage form, and the active ingredient will be far less soluble in the abuse-route mucosa (nasal, vaginal, rectal). However, it is important to note, the drug will perform properly when used as intended by oral administration -- and when taken as prescribed, the release of the drug is not accelerated by drinking alcohol.

As for an integrated commercial offering covering other popular pain medications, Pisgah is continuing their research efforts while aggressively pursuing a development program for hydrocodone / acetaminophen combination products. In laboratory testing, Pisgah has shown they can "adjust" the properties of the new salts to yield immediate or controlled release versions. In general, the drug development pathway can be quite tortuous with unexpected events occurring, such as the FDA's mandate to reduce acetaminophen levels in products like Pisgah is developing. Fortunately, Pisgah sees this change more as an opportunity than a difficulty. As Pisgah's President, Bill Bristol, commented, "The mandated lower levels of acetaminophen allows for our technology's benefits to shine and not to be eclipsed by the health issues raised by higher levels of acetaminophen in combination products."

With eighteen patent applications and more on the way, Pisgah's intellectual property stable continues to grow, and is applicable to dozens of abused prescription drugs. Pisgah's technology provides an integrated solution to three principal concerns within the medical community: 1) improving patient care; 2) reducing medical practice liability; and 3) reducing barriers for treating pain. Pisgah anticipates its new products will be well-received by all stakeholders interested i
'/>"/>

SOURCE Pisgah Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NEURO-BIOTECH CORPORATION: Updates and latest developments
2. Former FDA Inspectors Train Medical Device, Pharmaceutical Companies How to Comply with Latest FDA Expectations for Validation and Part 11
3. Micro rheometer is latest Lab On a Chip device
4. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
5. CBR Pharma Insights' Latest Report, The New Era of Healthcare Reform - Supporting Revenue Growth through Understanding & Adaptation
6. Latest breakthroughs in technology expand options for diagnosing and treating disease
7. Healthcare Data Solutions Announces Latest Database, PrescriberPRO@Home.
8. The Latest in Digital USB Microscopes from Cole-Parmer
9. New STR Systems from Promega Comply with Latest DNA Database Standards
10. LS9 Secures $25 Million in Latest Round of Funding
11. World Renowned Scientists Gather to Share Latest Information on Answer to Wildlife Reproductive Fertility Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... and PARIS , July 1, ... Genective, key developer of biotech crops, today announce ... new generations of insect control traits. ... counter the realities of advancing insect resistance. We ... unique insect control technology with Genective,s capability in ...
(Date:7/1/2015)... 2015  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced that the company will ... 5:45 p.m. EDT following its presentation of RVT-101 ... 2015 (AAIC). The event will ... Lawrence Friedhoff , Chief Development Officer, will ...
(Date:7/1/2015)... ... July 01, 2015 , ... NEMA 4 (IP66) Medical Joysticks ... Medical Joysticks have an impermeable molecular barrier protection against bio-hazardous agents. Original ... will increase healthcare worker safety and reduce financial costs. , CTI Electronics announces ...
(Date:6/30/2015)... ... 30, 2015 , ... Park Systems , world-leader in ... into new classes of Nanoscale Graphene-based materials poised to revolutionize industries such as ... of the 21st Century' by the researchers who were awarded the 2010 Nobel ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4
... SAN DIEGO, Jan. 6, 2011 Ardea Biosciences, Inc. ... top-line results from its Phase 2b study of RDEA594 ... the treatment of gout, allopurinol.  Allopurinol currently accounts for ... gout prescription medications; however, in controlled trials, only 30-40% ...
... Jan. 6, 2011 Vista Partners announced today ... (Nasdaq: OPXA ) and raised its twelve ... Analyst at Vista Partners stated, "Opexa announced yesterday that their ... treatment of Multiple sclerosis , is now positioned from ...
... 2011 GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical ... focusing on the early diagnosis and preventive treatment of ... two U.S. events: the 28th J.P. Morgan Healthcare Conference ... Showcase (from January 10th to 12th, 2011). ...
Cached Biology Technology:Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 2Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 3Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 4Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 5Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 6Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 7Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Raises Target Price From $4.40 to $6.50 2GENFIT: Strong U.S. Exposure for Its Biomarker Activity 2GENFIT: Strong U.S. Exposure for Its Biomarker Activity 3
(Date:7/2/2015)... Fingerprint Cards has received an order ... from the distributor World Peace Industrial Group (WPI), part of ... Asia . Deliveries are planned to take place ... by smartphone manufacturers in Asia . The ... revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
(Date:6/24/2015)... 24, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Sharp has selected its industry-leading ... for its latest flagship smartphone device, the AQUOS ... million shipments of its fingerprint ID sensor technology, ... scalability and leadership in the biometrics market through ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... British Columbia researchers have identified a small virus that ... size, rescuing the infected zooplankton from certain death. The ... jumping genes found in other organisms. The study, ... Matthias Fischer, is published online today in Science Express. ...
... at managing environmental impacts of agriculture have spurred ... and natural fertilizers for commercial applications. Many organic ... other processing industries. In Mississippi, where the poultry ... each year, and annual chicken litter production is ...
... New University of Georgia research has identified a protein ... of the most common drugs used to treat pancreatic cancer. ... journal Cancer Research, found that a cell-surface protein ... reduced in function in two thirds of pancreatic tumors. By ...
Cached Biology News:'David and Goliath' viruses shed light on the origin of jumping genes: UBC study 2Chicken litter provides organic alternative to synthetic fertilizers 2Researchers find possible new treatment strategies for pancreatic cancer 2
... Fluoroskan Ascent is a ... flexibility for all kinds of ... research and for clinical applications. ... biology are all important application ...
... SpeedVac Concentrator, the SPD series takes the ... modern twist., The SPD121P SpeedVac comes equipped ... optimizing runs; preventing samples from freezing; and ... the end-users preset level., Standard features on ...
... desktop unit ideal for use in laboratories with ... speed set at 12 rpm , Temperature ... Bottle capacity of four 35 x 150mm bottles, ... bottles , Consistent, repeatable results achieved with ...
... Savant SpeedVac Concentrators set the standard for centrifugal ... uses a combination of centrifugal force, heat and ... run., SC110A comes equipped with:, , TEFLON-coated ... , Three ...
Biology Products: